Sagimet Biosciences Revenue

Revenue (ttm)

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

Market Cap

247.49M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	-	-	-
Dec 31, 2023	2.00M	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
UnitedHealth Group	435.16B
Johnson & Johnson	92.15B
Merck & Co.	64.24B
AbbVie	59.64B
Eli Lilly and Company	59.42B
AstraZeneca	56.50B
Novartis AG	56.37B
Novo Nordisk	49.11B

Revenue Rankings

SGMT News

11 days ago - Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
21 days ago - Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewsWire
21 days ago - Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration - PRNewsWire
4 weeks ago - Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts - Seeking Alpha
4 weeks ago - Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
6 weeks ago - Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis - GlobeNewsWire
7 weeks ago - Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit - GlobeNewsWire
2 months ago - Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha

More News